Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2004 Dec;13(5-6):361–364. doi: 10.1155/S0962935104000535

The effects of hemodialysis and peritoneal dialysis on serum homocysteine and C-reactive protein levels.

Ali Borazan 1, Selim Aydemir 1, Mehmet Sert 1, Ahmet Yilmaz 1
PMCID: PMC1781575  PMID: 15770053

Abstract

OBJECTIVES: In this study, we aimed to investigate plasma homocysteine (Hcy) and serum C-reactive protein (CRP) levels in hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) patients, and the relation among them. MATERIALS AND METHODS: This study was carriedout on 52 HD patients, 26 CAPD patients and a control group of 22 healthy persons. Blood samples were taken from the patients for Hcy and CRP measurements. RESULTS: Serum CRP level was found to be high in 48.1% of HD patients, 69.2% of CAPD patients and 4.5% of the healthy control group. Plasma Hcy level was found out to be above the normal limits in 73.1% of HD patients, 65.4% of CAPD patients and 9% of the healthy control group. There was a significant positive relation (r = 0.384, p < 0.001) between the levels of plasma Hcy and serum CRP in HD and CAPD patients. CONCLUSION: The high levels of Hcy and CRP were found out to be higher in HD and CAPD patients than in the control group. In order to determine the risk rate of Hcy and CRP for coronary artery disease, extensive investigations are required in patients with chronic renal failure that also have coronary artery disease.

Full Text

The Full Text of this article is available as a PDF (81.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayés Beatriu, Pastor M. Cruz, Bonal Jordi, Juncà Jordi, Hernandez José M., Riutort Nadal, Foraster Andreu, Romero Ramón. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant. 2003 Jan;18(1):106–112. doi: 10.1093/ndt/18.1.106. [DOI] [PubMed] [Google Scholar]
  2. Bostom A. G., Shemin D., Verhoef P., Nadeau M. R., Jacques P. F., Selhub J., Dworkin L., Rosenberg I. H. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2554–2558. doi: 10.1161/01.atv.17.11.2554. [DOI] [PubMed] [Google Scholar]
  3. Chung S. H., Heimbürger O., Stenvinkel P., Bergström J., Lindholm B. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant. 2001 Nov;16(11):2240–2245. doi: 10.1093/ndt/16.11.2240. [DOI] [PubMed] [Google Scholar]
  4. Clyne N., Lins L. E., Pehrsson S. K. Occurrence and significance of heart disease in uraemia. An autopsy study. Scand J Urol Nephrol. 1986;20(4):307–311. doi: 10.3109/00365598609024517. [DOI] [PubMed] [Google Scholar]
  5. Danesh J., Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk. 1998 Aug;5(4):229–232. [PubMed] [Google Scholar]
  6. Eikelboom J. W., Hankey G. J. Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. Curr Opin Nephrol Hypertens. 2001 May;10(3):377–383. doi: 10.1097/00041552-200105000-00013. [DOI] [PubMed] [Google Scholar]
  7. Foley R. N., Parfrey P. S., Sarnak M. J. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998 Dec;9(12 Suppl):S16–S23. [PubMed] [Google Scholar]
  8. Levey A. S., Beto J. A., Coronado B. E., Eknoyan G., Foley R. N., Kasiske B. L., Klag M. J., Mailloux L. U., Manske C. L., Meyer K. B. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998 Nov;32(5):853–906. doi: 10.1016/s0272-6386(98)70145-3. [DOI] [PubMed] [Google Scholar]
  9. Manns B. J., Burgess E. D., Hyndman M. E., Parsons H. G., Schaefer J. P., Scott-Douglas N. W. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis. 1999 Oct;34(4):669–677. doi: 10.1016/S0272-6386(99)70392-6. [DOI] [PubMed] [Google Scholar]
  10. Moustapha A., Gupta A., Robinson K., Arheart K., Jacobsen D. W., Schreiber M. J., Dennis V. W. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int. 1999 Apr;55(4):1470–1475. doi: 10.1046/j.1523-1755.1999.00378.x. [DOI] [PubMed] [Google Scholar]
  11. Owen W. F., Lowrie E. G. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 1998 Aug;54(2):627–636. doi: 10.1046/j.1523-1755.1998.00032.x. [DOI] [PubMed] [Google Scholar]
  12. Rostand S. G., Kirk K. A., Rutsky E. A. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int. 1984 Apr;25(4):653–659. doi: 10.1038/ki.1984.70. [DOI] [PubMed] [Google Scholar]
  13. Shemin D., Lapane K. L., Bausserman L., Kanaan E., Kahn S., Dworkin L., Bostom A. G. Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. J Am Soc Nephrol. 1999 May;10(5):1095–1099. doi: 10.1681/ASN.V1051095. [DOI] [PubMed] [Google Scholar]
  14. Stenvinkel P., Heimbürger O., Paultre F., Diczfalusy U., Wang T., Berglund L., Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999 May;55(5):1899–1911. doi: 10.1046/j.1523-1755.1999.00422.x. [DOI] [PubMed] [Google Scholar]
  15. Zimmermann J., Herrlinger S., Pruy A., Metzger T., Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999 Feb;55(2):648–658. doi: 10.1046/j.1523-1755.1999.00273.x. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES